Clinical Trials Logo

Immune Thrombocytopenia clinical trials

View clinical trials related to Immune Thrombocytopenia.

Filter by:

NCT ID: NCT06417398 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Start date: May 14, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID. To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID. To evaluate the initial efficacy of UTAA09 injection in the treatment of R/R AID subjects. To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects.

NCT ID: NCT06291415 Recruiting - Hemorrhage Clinical Trials

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Start date: April 2, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.

NCT ID: NCT06287567 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

Start date: March 20, 2024
Phase: Phase 4
Study type: Interventional

This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy

NCT ID: NCT06281327 Recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Start date: March 2024
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.

NCT ID: NCT06199089 Recruiting - Clinical trials for Immune Thrombocytopenia

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Start date: January 16, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of CM313 in the treatment of immune thrombocytopenia in patients who have failed glucocorticoid therapy.

NCT ID: NCT06190145 Recruiting - Clinical trials for Immune Thrombocytopenia

Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

Single-arm, open-label, single-center study to evaluate the efficacy and safety of teriflunomide for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

NCT ID: NCT06176911 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP

NCT ID: NCT06176235 Recruiting - Clinical trials for Immune Thrombocytopenia

Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Start date: December 19, 2023
Phase: Phase 2
Study type: Interventional

A randomized, open-label, multicenter study to compare the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

NCT ID: NCT06168851 Recruiting - Clinical trials for Immune Thrombocytopenia

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Start date: December 28, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

NCT ID: NCT06094881 Recruiting - Clinical trials for Immune Thrombocytopenia

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Start date: December 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.